NVIDIA's retreat reveals the truth of AI-driven drug discovery
Time：
2026-02-28 20:00
Author：
xieyijun
Post-PARP Era: Synthetic Lethality in Search of Its Next Anchor
Synthetic Lethality: Seeking a New Dawn
Time：
2026-02-28 08:05
Author：
xieyijun
The "Battle of the Gods" for BCMA CAR-T
From undercurrents to head‑to‑head combat.
Time：
2026-02-27 08:22
Author：
xieyijun
"Oriental Redemption" of DNA Vaccine
Fosun Pharma makes a heavy investment bet
Time：
2026-02-25 21:34
Author：
xieyijun
Year of the Horse BD Kickoff: CTLA‑4 Makes a Comeback
The wave of global expansion continues unabated.
Time：
2026-02-23 22:06
Author：
xieyijun
PitchBook: China is becoming the birthplace of new drugs globally
A period of over twenty years of accumulation and gradual development
Time：
2026-02-22 17:15
Author：
xieyijun
iPS commercialization, in vivo therapy enters the "era of governance"
Time：
2026-02-21 15:42
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务